All News

Four urologists offer their takes on presidential candidates' health care plans.

If medical specialties were competing for which would have the most dire shortage of practicing physicians by 2025, urologists would likely win.

In this letter to the editor, Faris Azzouni, MD, makes his case for foreign urologists as a solution to the urologist shortage.

Treatment options for high-risk prostate cancer perform similarly. In a single-institution study, radical prostatectomy was associated with worse biochemical failure, less clinical failure, and superior prostate cancer-specific mortality compared with radiation therapy and brachytherapy, reported Jay P. Ciezki, MD, at the 2016 Genitourinary Cancers Symposium in San Francisco.

Gynecologists derive higher complication rates than urologists during the first 30 days following sling procedures for urinary incontinence, according to a multicenter study presented at the European Association of Urology annual congress in Munich, Germany.

"An abstract authored by Löppenberg et al is an interesting analysis of information from a respected prospective database examining variations in the quality of care provided to patients undergoing sling placement by gynecologists and urologists," write Seth A. Cohen, MD, and Shlomo Raz, MD.

"I have no personal experience with marijuana. But I do practice medicine in Colorado and given the state’s ongoing experiment with legal recreational marijuana, I am accumulating a significant amount of professional experience with the drug," writes Henry Rosevear, MD.

Four current clinical practice guidelines on prostate cancer provide urologists with valuable, evidence-based decision points about diagnosis and treatment while raising questions that will likely be addressed by future research.

A meta-analysis of 6,884 men with prostate cancer who underwent external beam radiation therapy reveals surprising findings about dose escalation.

UT SUO internship program member Robert M. Turner, II, MD, reports on a recent keynote addressing current coaching initiatives and their impact on outcomes.

In May 2013, the AUA and the American Society for Radiation Oncology released a joint guideline for radiotherapy after prostatectomy (J Urol 2013; 190:441-9). As a framework for practitioners caring for men who undergo surgery for treatment of prostate cancer, the evidence-based guideline contains nine statements that address use of adjuvant and salvage radiotherapy, conduct of a restaging evaluation, patient counseling, and a definition for biochemical recurrence

New clinical practice guidelines for the management of prostate cancer from the National Comprehensive Cancer Network expand the number of patients who may be considered for active surveillance to those with favorable intermediate-risk prostate cancer.

Years ago, decisions about screening men for PSA looked relatively straightforward. You offered screening to patients aged 40 or older, performed a biopsy on the ones with a total PSA >4.0 ng/mL, and offered treatment to those with positive biopsies. Today, conflicting guidelines and new techniques in cancer detection and treatment have left clinicians with a more complicated puzzle. The good news, experts say, is that physicians who put these pieces together stand a better chance of protecting their patients’ health than ever before.

In its current iteration, the AUA's CRPC guideline contains 20 statements relating to treatments for six index patients defined by the presence or absence of metastatic disease, presence and degree of symptoms, ECOG performance status, and prior treatment with docetaxel (Taxotere) along with two statements on the use of preventive treatments for bone health.

A recent human study sought to replicate previous success seen in animal models of reperfusion injury, reports Urology Times SUO internship program member Katie Murray, DO.

Urology Times SUO internship program member Ryan Hutchinson, MD, reports on a presentation on plasmacytoid urothelial carcinoma and adenocarcinoma.

To guide you through the 2016 AUA annual meeting and help maximize your time, Urology Times’ editorial board has reviewed the program to identify the key trends and noteworthy research at this year’s meeting.

Urologists demonstrate several techniques to help the occasional AUS implanter avoid complications.

This video, from Andrew C. Paterson, MD, and Uwais B. Zaid, MD, describes a technique for the placement of the male bulbar artificial urinary sphincter.

A novel oral TRT agent, bladder control system, and localized prostate cancer agent are among other treatments in the pipeline discussed in this round-up.

Sean Elliott, MD, MS, presents a streamlined, 30-minute approach to AUS insertion.

Henry Rosevear, MD, discusses Enhanced Recovery After Surgery, a protocol that allows urologists in the trenches to provide excellent perioperative care.

In this interview, Daniel W. Lin, MD, discusses the practical use of currently available molecular and genomic tests, cost and reimbursement considerations, the role of MRI, and what the future holds for biomarkers.

“Leaving the hospital every night becomes a bit of a mental cage match: Look up, see someone you know, and you may never get home,” writes Christopher Bayne, MD.

Findings from preoperative multiparametric magnetic resonance imaging may enhance risk stratification, surgical planning, and patient counseling for men with prostate cancer, according to researchers from the National Institutes of Health, Bethesda, MD.

C-11 choline positron emission tomography and multiparametric pelvic magnetic resonance imaging (pMRI) can be used successfully to identify recurrence patterns in patients with biochemical recurrence after radical prostatectomy.

In a head-to-head comparison, sunitinib (Sutent) prolonged radiographic progression-free survival compared with everolimus (Afinitor), but with greater toxicity, in patients with specific subtypes of metastatic renal cell carcinoma and non-clear cell histology, said Andrew J. Armstrong, MD, MSc.

Many approaches have been tried for reducing the rectal toxicity of radiotherapy (Radiat Oncol 2013; 8:96; Int J Radiat Oncol Biol Phys 2012; 82:1918-22; Radiat Oncol 2014; 9:96). This article discusses a newer therapy that involves the injection of a temporary hydrogel in the plane between the prostate and rectum.